What is Emgality?
Emgality (galcanezumab-gnlm) is a prescription medication used to prevent migraines in adults. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) antagonists, which target a protein involved in migraine attacks.[1]
How Does Emgality Work?
Emgality blocks CGRP, a neurotransmitter that triggers migraine pain, inflammation, and blood vessel dilation in the brain. Administered as a monthly subcutaneous injection (120 mg after an optional 240 mg loading dose), it reduces the frequency of monthly migraine days.[1][2]
What Conditions Does Emgality Treat?
The FDA approved Emgality in 2018 specifically for episodic (4-14 headache days per month) and chronic (15 or more headache days per month) migraine prevention in adults. It does not treat acute migraines or cluster headaches.[1][3]
Who Makes Emgality?
Eli Lilly and Company manufactures and markets Emgality in the United States.[1]
Dosage and Administration
Patients self-inject 120 mg once monthly using a prefilled autoinjector or syringe, typically in the abdomen, thigh, or upper arm. A 240 mg loading dose (two 120 mg injections) is given at the first use.[1][2]
Common Side Effects
Most patients experience no serious issues, but injection site reactions (redness, pain, itching) occur in about 18% of users. Hypersensitivity reactions are rare but possible; allergic symptoms like rash or swelling require immediate medical attention. No black box warnings apply.[1][3]
Cost and Access
A 30-day supply costs $800-$1,000 without insurance, though patient assistance programs from Lilly can reduce this for eligible users. It's available via pharmacies with a prescription.[4]
When Does Emgality's Patent Expire?
Key U.S. patents for Emgality, including composition-of-matter protections, extend to at least 2033, with some formulation patents to 2036. Challenges from generics are ongoing; check DrugPatentWatch.com for litigation updates and expiry details.5
[1]: https://www.emgality.com
[2]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761063s015lbl.pdf
[3]: https://www.mayoclinic.org/drugs-supplements/galcanezumab-subcutaneous-route/description/drg-20444084
[4]: https://www.goodrx.com/emgality